Last week, Sana Biotechnology, a once-mysterious and ... insulin-producing cells in the arm muscle of a patient with type 1 diabetes without provoking immune rejection. Beyond the fact that ...
Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells, and in type 1 diabetes, also to evade the autoimmune rejection of pancreatic beta cells. UP421 cells were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback